Scienture Holdings, Inc. (SCNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has a cash flow conversion efficiency ratio of 0.000x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($66.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scienture Holdings, Inc. (SCNX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Scienture Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scienture Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scienture Holdings, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Citius Pharmaceuticals Inc
NASDAQ:CTXR
|
-0.019x |
|
GigaMedia Limited
F:GIFN
|
N/A |
|
Leyand International Tbk
JK:LAPD
|
0.140x |
|
Bina Darulaman Bhd
KLSE:6173
|
-0.030x |
|
Libet S.A.
WAR:LBT
|
-0.026x |
|
Applied Therapeutics Inc
NASDAQ:APLT
|
32.800x |
|
Bodycote PLC
LSE:BOY
|
0.096x |
|
BBI Development S.A.
WAR:BBD
|
0.056x |
Annual Cash Flow Conversion Efficiency for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scienture Holdings, Inc. from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see SCNX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.12 Million | $-13.38 Billion | -190.850x | -105688.08% |
| 2024-12-31 | $79.07 Million | $-14.27 Million | -0.180x | +95.60% |
| 2023-12-31 | $542.35K | $-2.23 Million | -4.103x | +10.09% |
| 2022-12-31 | $342.87K | $-1.56 Million | -4.563x | -570.44% |
| 2021-12-31 | $3.77 Million | $-2.57 Million | -0.681x | -166.73% |
| 2020-12-31 | $8.68 Million | $-2.21 Million | -0.255x | -845.21% |
| 2019-12-31 | $4.14 Million | $141.78K | 0.034x | -89.42% |
| 2018-12-31 | $844.67K | $273.39K | 0.324x | +158.81% |
| 2017-12-31 | $-311.93K | $171.67K | -0.550x | -148.11% |
| 2016-12-31 | $-1.15 Million | $-1.31 Million | 1.144x | +115.48% |
| 2015-12-31 | $267.02K | $-1.97 Million | -7.392x | -364.14% |
| 2014-12-31 | $668.44K | $-1.06 Million | -1.593x | +75.32% |
| 2013-12-31 | $130.87K | $-844.58K | -6.454x | -1100255.67% |
| 2008-12-31 | $-48.01 Million | $-28.16K | 0.001x | -99.93% |
| 2007-12-31 | $-18.51K | $-16.07K | 0.868x | +234.87% |
| 2006-12-31 | $9.67K | $-6.22K | -0.644x | -- |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more